Fennec Pharmaceuticals IncFENC
Price$10.33Intrinsic value$16.1056% above price

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $59.2M+24.6% YoYTTM through 30 Jun 2026
Net Income -$3.3MTTM through 30 Jun 2026
Free Cash Flow -$2MTTM through 30 Jun 2026

Margins

Current
Gross Margin96.2%
EBITDA Margin-1.9%
Operating Margin-0.8%
Net Margin-5.5%

Returns

0.5%ROE
-11.7%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio6.98x
Net Debt-$40.2Mnet cash position
Cash & Equivalents$41.2M

Quality Metrics

Altman Z-Score4.44
Piotroski F-Score3 / 9
FCF Margin-3.4%
Rule of 4014.5
Earnings-Beat Rate50.0%

Multi-Year Trend

Revenue
'18'19'20'22'23'24'25
FY2025: $44.6M
Diluted EPS-$0.12TTM
'19'20'21'22'23'24'25
FY2025: $-0.34

Dividend

No dividend

Capital Allocation

R&D Spend$216K
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.